PBYI PUMA BIOTECHNOLOGY, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401667 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.4%
TTM net income YoY-35.6%
TTM EPS YoY-38.7%
Revenue 3-yr CAGR0.4%
Net income 3-yr CAGR85.8%
Margins
Gross margin73.6%
Operating margin11.3%
Net margin10.3%
FCF margin19.9%
EBITDA margin15.7%
Returns
ROE18.2%
ROA11.7%
ROIC (approx.)26.1%
Asset turnover1.14x
Leverage & solvency
Liabilities / assets27.7%
Debt / equity0.00x
Current ratio3.03x
Interest coverage12.88x
Cash quality & payout
Operating cash flow / net income1.93x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue-0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $228.37M | $230.47M |
| Cost of revenue | $58.16M | $64.40M |
| Gross profit | $170.21M | $166.06M |
| R&D expense | $62.07M | $54.94M |
| SG&A expense | $70.85M | $80.16M |
| Operating income | $37.30M | $30.97M |
| Interest expense | $6.62M | $12.45M |
| Pretax income | $35.78M | $24.10M |
| Income tax | $4.67M | -$6.18M |
| Net income | $31.11M | $30.28M |
| EBITDA | $48.24M | $42.49M |
| EPS (basic) | 0.62 | 0.62 |
| EPS (diluted) | 0.61 | 0.62 |
| Weighted avg. shares (diluted) | 50.65M | 49.10M |
| Balance sheet | ||
| Cash & equivalents | $29.64M | $69.22M |
| Short-term investments | $67.89M | $31.75M |
| Receivables | $53.65M | $32.01M |
| Inventory | $5.51M | $8.72M |
| Current assets | $162.69M | $147.66M |
| PP&E, net | $187,000 | $515,000 |
| Intangibles | $41.39M | $51.13M |
| Total assets | $216.30M | $213.33M |
| Current liabilities | $81.25M | $96.11M |
| Short-term debt | $22.52M | $45.33M |
| Long-term debt | $0 | $21.72M |
| Total debt | $22.52M | $67.05M |
| Total liabilities | $85.96M | $121.21M |
| Shareholders' equity | $130.34M | $92.12M |
| Net debt | -$7.11M | -$2.17M |
| Shares outstanding | 50.41M | 49.11M |
| Cash flow statement | ||
| Operating cash flow | $41.80M | $38.92M |
| Capital expenditure | $71,000 | $56,000 |
| Free cash flow | $41.73M | $38.86M |
| Investing cash flow | -$36.19M | -$20.44M |
| Financing cash flow | -$45.20M | -$33.85M |
| Depreciation & amortization | $10.94M | $11.52M |
| Stock-based compensation | $6.94M | $8.24M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.